Reviva Pharmaceuticals (RVPH) News Today → America could fall from this event (From Porter & Company) (Ad) Free RVPH Stock Alerts $1.70 -0.17 (-9.09%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 8:00 AM | globenewswire.comReviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International ConferenceMay 10, 2024 | prnewswire.comRVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPHMay 9, 2024 | globenewswire.comReviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual MeetingMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 4, 2024 | morningstar.comReviva Pharmaceuticals Holdings Inc Ordinary Shares RVPHApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHApril 28, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHApril 25, 2024 | finance.yahoo.comRVPH: Full Year 2023 ResultsApril 25, 2024 | businesswire.comRVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPHApril 24, 2024 | marketbeat.comBrokers Set Expectations for Reviva Pharmaceuticals Holdings, Inc.'s Q1 2024 Earnings (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Equities research analysts at HC Wainwright cut their Q1 2024 EPS estimates for shares of Reviva Pharmaceuticals in a research report issued to clients and investors on Monday, April 22nd. HC Wainwright analyst R. Selvaraju now eApril 23, 2024 | marketbeat.comHC Wainwright Weighs in on Reviva Pharmaceuticals Holdings, Inc.'s Q1 2025 Earnings (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a research note issued on Monday, April 22nd. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.33) per sApril 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)April 22, 2024 | marketbeat.comReviva Pharmaceuticals (NASDAQ:RVPH) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Reviva Pharmaceuticals in a report on Monday.April 16, 2024 | marketbeat.comReviva Pharmaceuticals' (RVPH) "Speculative Buy" Rating Reiterated at BenchmarkBenchmark reissued a "speculative buy" rating and issued a $17.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday.April 15, 2024 | msn.comRVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER DataApril 15, 2024 | investorplace.comRVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023April 15, 2024 | finanznachrichten.deReviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in SchizophreniaApril 15, 2024 | finanznachrichten.deReviva Pharmaceuticals: Reviva Reports Full Year 2023 Financial Results and Recent Business HighlightsApril 15, 2024 | globenewswire.comReviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in SchizophreniaApril 15, 2024 | globenewswire.comReviva Reports Full Year 2023 Financial Results and Recent Business HighlightsApril 14, 2024 | marketbeat.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest UpdateReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 1,060,000 shares, a growth of 62.9% from the March 15th total of 650,700 shares. Based on an average daily volume of 331,800 shares, the days-to-cover ratio is currently 3.2 days.March 28, 2024 | finance.yahoo.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual MeetingMarch 28, 2024 | globenewswire.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual MeetingMarch 27, 2024 | finance.yahoo.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual MeetingMarch 25, 2024 | markets.businessinsider.comOptimistic Buy Rating for Reviva Pharmaceuticals Based on Brilaroxazine’s Broad Therapeutic PromiseMarch 25, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Reviva Pharmaceuticals in a report on Monday.March 15, 2024 | marketbeat.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Down 15.9% in FebruaryReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of a large decline in short interest in February. As of February 29th, there was short interest totalling 858,100 shares, a decline of 15.9% from the February 14th total of 1,020,000 shares. Based on an average daily volume of 432,200 shares, the days-to-cover ratio is currently 2.0 days.March 14, 2024 | finance.yahoo.comRVPH Mar 2024 3.000 putMarch 11, 2024 | globenewswire.comReviva to Present at the UBS Virtual CNS DayMarch 7, 2024 | globenewswire.comReviva to Present at the 36th Annual ROTH ConferenceMarch 3, 2024 | finance.yahoo.comRVPH Mar 2024 3.500 callFebruary 29, 2024 | finance.yahoo.comRVPH Jan 2026 5.500 callFebruary 27, 2024 | finance.yahoo.comRVPH Apr 2024 12.500 callFebruary 23, 2024 | ca.finance.yahoo.comRVPH Mar 2024 4.500 putFebruary 22, 2024 | benzinga.comReviva Pharmaceuticals Stock (NASDAQ:RVPH), Short Interest ReportFebruary 20, 2024 | finance.yahoo.comReviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 20, 2024 | globenewswire.comReviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 17, 2024 | finance.yahoo.comRVPH Mar 2024 3.000 callFebruary 17, 2024 | finance.yahoo.comRVPH Mar 2024 5.500 putJanuary 25, 2024 | finance.yahoo.comReviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select ConferenceJanuary 17, 2024 | ca.finance.yahoo.comRVPH Jan 2025 7.500 callJanuary 10, 2024 | finanznachrichten.deReviva Pharmaceuticals: Reviva to Present at Webull LIVE! Healthcare Webinar on January 17January 10, 2024 | finance.yahoo.comReviva to Present at Webull LIVE! Healthcare Webinar on January 17January 4, 2024 | finance.yahoo.comReviva Provides Corporate and Program Updates and Highlights Key Upcoming MilestonesDecember 28, 2023 | benzinga.comReviva Pharmaceuticals Stock (NASDAQ:RVPH) Dividends: History, Yield and DatesDecember 26, 2023 | finance.yahoo.comKaruna downgraded, Arm target raised: Wall Street's top analyst callsDecember 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alector (ALEC), Reviva Pharmaceuticals Holdings (RVPH) and Oculis Holding (OCS)November 30, 2023 | finance.yahoo.comReviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceNovember 27, 2023 | msn.comReviva Pharmaceuticals Holdings (RVPH) Price Target Increased by 13.48% to 17.17November 21, 2023 | finanznachrichten.deReviva Pharmaceuticals: Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Millionaire Says: “Buy This $11 AI Coin.” (Ad)Right now, you can harness the power of two bull markets... Artificial intelligence...And cryptos. Find out more about this $11 AI Coin right now RVPH Media Mentions By Week RVPH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVPH News Sentiment▼0.350.57▲Average Medical News Sentiment RVPH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVPH Articles This Week▼41▲RVPH Articles Average Week Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ANEB News LPTX News AFMD News SLS News TPST News LFVN News VTVT News HOOK News JAGX News CRVS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVPH) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityNot Trump. Not Biden. But ___________.The Freeport SocietyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
